A lower proportion of patients with HR+/HER2− cancers had 0/1 +SLNs when compared with patients with HER2+ and triple negative breast cancers (TNBC) (76% versus 81% and 85%, respectively, p < 0.001). This evidence concerns the gene ERBB2 and triple-negative breast carcinoma.